Результаты поиска

Investigative biological therapies for primary Sjögren's syndrome.

Primary Sjögren's syndrome (pSS) is a chronic, systemic autoimmune disease characterized by dryness of the eyes and mouth. The histological feature is mononuclear cell infiltration in exocrine glands, primarily salivary and lachrymal glands. As the disease progresses, some other tissues and organs may be involved and extraglandular manifestations ensue. The major current treatments are palliative and empirical, and in most cases the outcomes are not satisfactory. Emerging data indicate a critical role of lymphocytes in its development and progression. While pioneering work targeting B cells ha

Совпадение в полном тексте источника
… Ann Rheum Dis 2019 ; 78 : 641 - 7 . 30826774 10.1136/annrheumdis-2018-214720 51 Lis K , Kuzawinska O , Balkowiec-Iskra E . Tumor necrosis factor inhibitors – state of knowledge . … Ann Rheum Dis 2019 ; 78 : 249 - 60 . 30472652 10.1136/annrheumdis-2017-212619 PMC6352416 81 Pollard RP , Abdulahad WH , Vissink A , et al . …

Пациенты с системным склерозом с синдромом перепадов и без него демонстрируют схожие микроваскулярные аномалии.

ВВЕДЕНИЕ: видеокаплироскопия с капиллярным покрытием (NVC) является полезным инструментом для измерения плотности капилляров (CD) и параметров капиллярной морфологии и используется главным образом в системном склерозе (SSc). ЦЕЛЬ: Мы стремились оценить распространенность SSc-образца и CD-диска в различных соединительных болезнях тканей (КТД). МЕТОДЫ: NVC был выполнен на 268 Пациенты с КТД. В состав контрольных групп входили: 104 добровольцы (ГТС) и 36 Первичные пациенты Рейно. МЕРОПРИЯТИЯ: Уменьшившийся компакт-диск был более распространен в SSc, системном волшебном эретематосе (SLE), подстрек

Совпадение в аннотации оригинала
INTRODUCTION: Nailfold video capillaroscopy (NVC) is a useful tool for measuring capillary density (CD) and capillary morphology parameters … p syndrome. An SSc pattern was significantly more prevalent in SLE (23%), SSc (82%), IIM (35%), and rheumatoid arthritis (17%) compared with both control groups. The prevalence of an elevated microangiopathy evaluation score (MES) was significantly higher in SLE, SSc, and IIM than in the HVs. CONCLUSION: The presence of another CTD in SSc did not influ …

Advances in drug therapy for systemic lupus erythematosus.

Systemic lupus erythematosus (SLE) is an autoimmune disorder that afflicts 500,000 people in the United States. There has not been a new SLE drug approved in the United States since 1958. However, a guidance document issued by the Food and Drug Administration in 2005 provided a roadmap for investigators which spawned numerous ongoing clinical trials. Among these, Belimumab, a monoclonal antibody to soluble B lymphocyte stimulator, met its primary endpoints in two large trials and will probably obtain FDA approval soon. Other promising agents targeting a variety of mechanisms of action are curr

Совпадение в полном тексте источника
… 2010 62 377 387 10.1002/art.27601 20533545 Boumpas DR Furie R Manzi S Ilei GG Wallace DJ Balow JE Vaishnaw A A short course of BG9588 (anti-CD 40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis Arthritis Rheum 2003 48 719 … DJ Stohl W Furie RA Lisse JR Mc Kay JD Merrill JT Petri MA Ginzler EM Chatham WW McCune WJ Fernandez V Chevrier MR Zhong ZJ Freimuth WW A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus Arthritis Rheum 2009 …

Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry.

INTRODUCTION: This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population. METHODS: HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single-center biological disease-modifying anti-rheumatic drug (bDMARD) registry since 2005. Patients with IA, including rheumatoid arthritis, spondyloarthritis, or psoriatic arthritis who had at least one visit after the TNFi were screened from 2005 to November 2021. Standardized incidence rates …

Progress in Biological Therapies for Adult-Onset Still's Disease.

Adult-onset Still's disease (AOSD) is a rare multifactorial autoinflammatory disorder of unknown etiology, characterized by an excessive release of cytokines triggered by dysregulated inflammation and articular and systemic manifestations. The clinical spectrum of AOSD ranges from self-limiting forms with mild symptoms to life-threatening cases and presents clinical and biological similarities with the juvenile form (sJIA). Nowadays, the advances in biologic agents no longer limit the treatment to NSAIDs, glucocorticoids, or conventional synthetic DMARDs. The blockade of IL-1 and IL-6 is effec

Совпадение в полном тексте источника
… Ann Rheum Dis . 2001;60 Suppl 3(Suppl 3):iii55–iii57. doi: 10.1136/ard.60.90003.iii55 62. Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum . 2002;46(5):1171–1176. doi: 10.1002/art.10231 63. … Ann Rheum Dis . 2017;76(1):166–172. doi: 10.1136/annrheumdis-2015-209020 78. Benedetti FD, Brogan P, Grom A, et al. …

Immunosuppressants/Immunomodulators and Malignancy.

Individuals with immunosuppressive conditions are at a higher risk of developing malignancies than those in the general population. Immunosu … s vary depending on the type of drug administered before the onset of these diseases. Patients with rheumatoid arthritis (RA) are treated with long-term immunosuppressive medications, such as methotrexate (MTX). MTX is widely recognized as being associated with a specific type of lymphoproliferative disorder (LPD), known as MTX-associated LPD. Our recen …

Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner.

Systemic Lupus Erythematosus (SLE) is a complex chronic autoimmune disease that manifests a wide range of organ involvement. Traditionally, the diagnosis and management of SLE is provided at secondary and tertiary centers to ensure prompt initiation of treatment, adequate control of flares and prevention of irreversible organ damage. Notwithstanding, the role of primary care in SLE is also emerging as there are still significant unmet needs such as the diagnostic delay at the community level and the high burden of therapy- and disease-related comorbidities. In the present review, we summarize

Совпадение в полном тексте источника
… Ann Rheum Dis. (2016) 75:136–41. 10.1136/annrheumdis-2014-206334 17. Hill JC, Dunn KM, Lewis M, Mullis R, Main CJ, Foster NE, et al. A primary care back pain screening tool: identifying patient subgroups for initial treatment. Arthritis Rheum. (2008) 59:632–41. 10.1002/art.23563 18. Leonhardt T. … Ann Rheum Dis. (2012) 71:1771–82. 10.1136/annrheumdis-2012-201940 173. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. …

Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab.

Tocilizumab is a fully humanized monoclonal antibody against interleukin-6 receptors that was approved for the treatment of patients with rheumatoid arthritis (RA). Several lines of evidence, obtained both from conventional disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor (TNF) inhibitors, have supported the concept of "window of opportunity" as showing that these therapies consistently work better in early disease as compared to established RA. This review addresses the question of whether a window of opportunity gained with conventional DMARDs and TNF inhibitors can …

Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches.

Systemic sclerosis (SSc) is a systemic, immune-mediated chronic disorder characterized by small vessel alterations and progressive fibrosis of the skin and internal organs. The combination of a predisposing genetic background and triggering factors that causes a persistent activation of immune system at microvascular and tissue level is thought to be the pathogenetic driver of SSc. Endothelial alterations with subsequent myofibroblast activation, excessive extracellular matrix (ECM) deposition, and unrestrained tissue fibrosis are the pathogenetic steps responsible for the clinical manifestati

Совпадение в полном тексте источника
… Rheum. Dis. 2010;69:193–197. doi: 10.1136/ard.2008.095463. 68. Jordan S., Distler J.H.W., Maurer B., Huscher D., Van Laar J.M., Allanore Y., Distler O. Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann. Rheum. … Rheum. Dis. 2010;70:1340–1341. doi: 10.1136/ard.2010.137935. 137. Quillinan N., McIntosh D., Vernes J., Haq S., Denton C.P. Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): A phase II double-blind placebo-controlled trial. Ann. Rheum. …

Emerging B-Cell Therapies in Systemic Lupus Erythematosus.

Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease of unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising targets for novel SLE therapies. In 2011, belimumab (Benlysta®), a fully humanized monoclonal antibody inhibiting B-cell activation and proliferation, was the first medication in 50 years to be approved by the US Food and Drug Administration to treat adult SLE. This review discusses the current experience with B-cell-targeted therapies, including those targeting B-cell-surface antigens (rituximab, ocrelizumab, ofatumumab

Совпадение в полном тексте источника
… Arthritis Rheum . 2013;65:2368–2379. doi: 10.1002/art.38037 16. Furie RA, Aroca G, Alvarez A, et al. … Arthritis Rheum . 2006;54:2550–2557. doi: 10.1002/art.21955 63. Isenberg DA, Petri M, Kalunian K, et al. …

Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus.

Systemic lupus erythematosus (SLE, lupus) is a highly complex and heterogeneous autoimmune disease that most often afflicts women in their child-bearing years. It is characterized by circulating self-reactive antibodies that deposit in tissues, including skin, kidneys, and brain, and the ensuing inflammatory response can lead to irreparable tissue damage. Over many years, clinical trials in SLE have focused on agents that control B- and T-lymphocyte activation, and, with the single exception of an agent known as belimumab which targets the B-cell survival factor BAFF, they have been disappoint

Совпадение в полном тексте источника
… Arthritis Rheum (2012) 64(4):1215–26. 10.1002/art.34359 42. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. … Arthritis Rheum (2005) 52(7):2080–91. 10.1002/art.21138 111. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum (2001) 44(6):1313–9. 112. …

Novel and potential future therapeutic options in systemic autoimmune diseases.

Autoimmune inflammation is caused by the loss of tolerance to specific self-antigens and can result in organ-specific or systemic disorders. Systemic autoimmune diseases affect a significant portion of the population with an increasing rate of incidence, which means that is essential to have effective therapies to control these chronic disorders. Unfortunately, several patients with systemic autoimmune diseases do not respond at all or just partially respond to available conventional synthetic disease-modifying antirheumatic drugs and targeted therapies. However, during the past few years, som…

Усовершенствованные испытания самообслуживания в системном склерозе

Системный склероз — это системное аутоиммунное ревматическое заболевание, характеризующееся иммунными аномалиями, приводящее к васкулопатии и фиброзу. Тестирование самодисциплины становится все более важной частью диагностики и прогнозирования. Клинические врачи были ограничены антиядерной антителной (АНА), антитопоизомеразой I (также известной как anti-Scl-70) антитела и антисентромерные антитела. Многие врачи в настоящее время улучшили доступ к расширенному профилю автоантиорганических тестов. В этой статье мы анализируем эпидемиологию, клинические ассоциации и предсказанную ценность совреме

Совпадение в аннотации оригинала
Systemic sclerosis is a systemic autoimmune rheumatic disease characterized by immune abnormalities, leading to vasculopathy and fibrosis. Autoantibody testing has become an increasingly important part of diagnosis and prognostication. Clinicians have been limited to antinuclear antibody (ANA), antitopoisomerase I (also known as anti-Scl-70) antibody, and an…

Внезапная сердечная смерть при системном склерозе: диагностика для оценки риска и управления информацией

Сердечное заболевание является одной из основных причин смертности при системном склерозе (SSc), а внезапная сердечно-сосудистая смертность (SCD), как считается, чаще встречается в SSc, чем в целом по населению. Диффузный миокардиальный фиброз, миокардит и ишемическая болезнь сердца широко распространены в SSc и могут быть разумно гипотезы, что будет способствовать повышению риска СКД. Несмотря на это, СКР по-прежнему остается относительно недооцененной зоной SSc, где мало что известно о специфических для SSc факторах риска и возможностях первичной профилактики. В этом обзоре мы представляем о

Совпадение в полном тексте источника
… Arthritis Rheum. 2014;43:526–535. doi: 10.1016/j.semarthrit.2013.07.006. 35. Watad A., McGonagle D., Bragazzi N.L., Damiani G., Comaneshter D., Lidar M., Cohen A.D., Amital H. … Arthritis Rheum. 2011;63:3969–3978. doi: 10.1002/art.30614. 58. Follansbee W.P., Curtiss E.I., Rahko P.S., Medsger T.A., Lavine S.J., Owens G.R., Steen V. …

Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities.

Lupus nephritis (LN) is a frequent and serious complication of systemic lupus erythematosus (SLE), impairing patients' quality of life and significantly increasing mortality. Despite optimizing the use of conventional immunosuppressants and other biological drugs, its management remains unsatisfactory. This is mainly due to the heterogeneity of SLE, but also to insufficiently effective treatment regimens and clinical trial limitations (strict criteria, low number of patients included, and side effects). Most clinical trials of new biological therapies have failed to meet their primary endpoint

Совпадение в полном тексте источника
… Ann Rheum Dis . 2016;75(2):323–331. doi: 10.1136/annrheumdis-2015-207653 69. Merrill JT, Van Vollenhoven RF, Buyon JP, et al. … Ann Rheum Dis . 2023;82(Suppl 1):90.2–91. doi: 10.1136/annrheumdis-2023-eular.1727 76. Merrill JT, Shanahan WR, Scheinberg M. …

Role of B-Cell in the Pathogenesis of Systemic Sclerosis.

Systemic sclerosis (SSc) is a rare multisystem autoimmune disease, characterized by fibrosis, vasculopathy, and autoimmunity. Recent advances have highlighted the significant implications of B-cells in SSc. B-cells are present in affected organs, their subpopulations are disrupted, and they display an activated phenotype, and the regulatory capacities of B-cells are impaired, as illustrated by the decrease in the IL-10+ producing B-cell subpopulation or the inhibitory membrane co-receptor density. Recent multi-omics evidence highlights the role of B-cells mainly in the early stage of SSc and p

Совпадение в полном тексте источника
… Ann Rheum Dis ( 2017 ) 76 : 1897–905 . doi: 10.1136/annrheumdis-2017-211448 28835464 4 Thoreau B Chaigne B Renaud A Mouthon L . Pathophysiology of Systemic Sclerosis . … Ann Rheum Dis ( 2012 ) 71 : 596 – 605 . doi: 10.1136/annrheumdis-2011-200195 22084393 79 O’Reilly S Ciechomska M Cant R van Laar JM . …

CAR-T cells targeting CD19 for the treatment of ANCA vasculitis.

Autoimmune anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis (AAV) and glomerulonephritis is characterized by the presence of autoantibodies (so-called ANCA), which, by binding to the body's own antigens, lead to damaged blood vessels (vasculitis) and subsequently to organ damage, particularly of the kidneys. The primary endogenous antigens are the enzymes proteinase 3 (PR3) and myeloperoxidase (MPO) expressed by neutrophil granulocytes and monocytes. In addition to the autoantibodies, both T-cellular response to those autoantigens and monocyte/macrophage-mediated process

Совпадение в полном тексте источника
… Ann Rheum Dis 2008;67:1004–10. 10.1136/ard.2007.071936 29. Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488–94. 10.1136/ard.2010.137778 30. Little MA, Nightingale P, Verburgh CA et al. … Ann Rheum Dis 2024;83:1597–8. 10.1136/ard-2024-226017 61. Lidar M, Rimar D, David P et al. CD-19 CAR-T cells for polyrefractory rheumatoid arthritis. Ann Rheum Dis 2025;84:370–2. 10.1136/ard-2024-226437 62. Schmelz JL, Navsaria L, Goswamy R et al. …

Animal Models in Rheumatoid Arthritis: Is There a Correlation Between Autoantibodies in Human Pathology and Animal Models?

RA is a chronic autoimmune disease characterized by synovial inflammation and joint damage, driven by autoantibodies such as ACPA, anti-CarP and RF. These autoantibodies, influenced by genetic and environmental factors, play a crucial role in RA pathogenesis through post-translational modifications like citrullination, carbamylation, and acetylation. The early detection of ACPA provides a potential window for intervention, while anti-CarP antibodies correlate with severe disease progression and RF aids in diagnosis. Translating these findings from human pathology to animal models presents sign

Совпадение в полном тексте источника
… Rheum. Dis. 2015 74 949 950 10.1136/annrheumdis-2014-206797 25653200 17. Gioud-Paquet M. Auvinet M. Raffin T. Girard P. Bouvier M. Lejeune E. Monier J.C. IgM Rheumatoid Factor (RF), IgA RF, IgE RF, and IgG RF Detected by ELISA in Rheumatoid Arthritis Ann. Rheum. … Correlation with Disease Progression Arthritis Rheum. 1996 39 1720 1727 10.1002/art.1780391015 8843863 84. Mullazehi M. Mathsson L. Lampa J. Rönnelid J. …

Advances in the treatment of systemic lupus erythematosus: Biologicals, small-molecular agents, and cell-depleting therapies coming to the clinic.

Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and-until recently-limited treatment options all associated with considerable downsides. However, a major change in this situation is currently taking place. Over the past few years, several new biological therapeutics have been approved for the treatment of SLE (belimumab and anifrolumab) or specifically for its renal organ manifestation (obinutuzumab), along with one new small molecular treatment for t

Совпадение в полном тексте источника
… Ann Rheum Dis. 2012;71(8):1343–9. 39. … Ann Rheum Dis. 2020;79(1):141–149. 113. …

Systemic lupus erythematosus: pathogenesis and targeted therapy.

Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by dysregulated immune responses and autoantibody production, which affects multiple organs and varies in clinical presentation and disease severity. The development of SLE is intricate, encompassing dysregulation within the immune system, a collapse of immunological tolerance, genetic susceptibilities to the disease, and a variety of environmental factors that can act as triggers. This review provides a comprehensive discussion of the pathogenesis and treatment strategies of SLE and focuses on the progress